Tretinoin may worsen hair loss by inducing premature hairfollicle regression. It can be used with minoxidil to increase absorption but should not be used alone.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
A Swiss product called Redensyl, which is supposed to target hairfollicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hairfollicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
PP405, a topical LDH inhibitor, has shown to stimulate hairfollicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses concerns about the potential risk of cancer from creating new hairfollicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Glycosaminoglycans are important for hair growth, and combining minoxidil with tretinoin and Biopeptide-CL may enhance hair growth by boosting glycosaminoglycan levels and improving the hairfollicle environment. Users discussed the potential effectiveness and future of these treatments.
The post is an update on the user's hair loss journey. They have a strong hairfollicle that has remained unaffected by hair loss for almost 3 years. The user is starting finasteride and using ketoconazole, alfatradiol, and oral castor oil for hair maintenance.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
The conversation discusses potential future hair loss treatments, including SCUBE3, hairfollicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.
The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hairfollicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.
The conversation discusses an interview with Dr. Tsuji about hairfollicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hairfollicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
HairClone aims to rejuvenate miniaturizing hairfollicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hairfollicles, but full regenerative treatments will take many years to develop.
A gel of keratin microspheres promotes hairfollicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hairfollicle sensitivity to DHT.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hairfollicle stem cells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.
How Finasteride and Dutasteride help reduce hair loss by reducing the amount of DHT in scalp areas, as well as discussing factors such as sensitivity to DHT, 5α-reductase expression in different parts of the hairfollicle, and scalp tension.
The conversation is about a hair loss treatment routine involving dermarolling, finasteride, minoxidil, and natural oils. Suggestions include using shorter needles for better absorption of treatments and longer needles less frequently for hairfollicle regeneration.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hairfollicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hairfollicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
A 24-year-old woman with thinning hair is using Minoxidil, saw palmetto, biotin, rosemary oil, and ketoconazole. She seeks advice on whether to try finasteride or dutasteride, the effects of Minoxidil shedding, and the significance of her hairfollicle condition.
The user shared a 3-month progress update on hair loss treatment using finasteride (1 mg), minoxidil (5% once or twice daily), and microneedling (1.5mm every 2 weeks) with no side effects. Commenters are impressed, discussing hairfollicle revival and the user's method, noting the hair appears darker.
The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hairfollicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.
A user shared their 3-month progress using 1mg oral finasteride daily and 5% topical minoxidil twice daily, along with Pura D’Or anti-thinning shampoo and a scalp massager. They noticed initial worsening but later saw hairfollicle recovery.
The conversation discusses expectations for the release of Breezula, a new hair loss treatment, and compares it to existing treatments like finasteride. Some believe Breezula could be a game-changer due to fewer side effects, while others await more permanent solutions like hairfollicle cloning.